




Figure 1. Relative fluorescence from HeLa cells treated with **3** (100 μ M) or the complex **2:AF** (100 μ M) under various conditions.

suggesting that the process is general across many cell lines. Localization of **3** was further probed in HeLa cells using fluorescence microscopy.

Internalization of lipids was energy dependent suggesting that it is facilitated by endocytosis.¹⁹ When incubations of HeLa cells with **3** or the complex **2:AF** were carried out at 4 °C, fluorescence from the cells decreased significantly. Indeed, only 39% and 57% of fluorescence was detectable when compared to the experiment at 37 °C for **3** and the **2:AF** complex, respectively (Figure 1). Furthermore, addition of sodium azide, an ATP depleting poison, and a known inhibitor of endocytosis, also resulted in a 21% decrease in fluorescence. These experiments implicate endocytosis as the primary mechanism of transport of the exogenous materials.^{34,35} We further interrogated whether endocytosis was orchestrated via a particular pathway. Participation of clathrin coated pits is frequently invoked in endocytic events, and it can be disrupted by incubation under hypertonic conditions (400 mM sucrose).³⁶ Indeed, when HeLa cells were treated with **3** or the **2:AF** complex under 400 mM sucrose, the fluorescence from the cells was diminished by 61% and 55%, respectively. These results were further corroborated with fluorescence microscopy of the resultant cells (see Supporting Information).

The ability of the transport agents to deliver macromolecules across membranes was investigated by incubation of HeLa cells with each of the preformed complexes **1:AF**, **2:AF**, and **4:AF** in separate experiments. The cells were pelleted by centrifugation twice and washed with PBS, resuspended in buffer, and then examined by microscopy or fluorescence counting. All agents were effective at ferrying **AF** into the cell. In contrast, neither **AF** nor the **AF:biotin** complex were by themselves able to traverse the membrane, resulting in cells that were minimally fluorescent. It has been previously established that the binding affinity of lipid–biotin conjugates to **AF** is several orders of magnitude less tight than biotin.^{37,38} When free biotin (≥ 5 equiv, 1 h) was allowed to equilibrate with **2:AF** prior to incubation with HeLa cells, the cells only exhibited background levels of fluorescence.

To assess what fraction of **3** or the complex **2:AF** resides on the outer leaflet of the plasma membrane, we subjected cells to reduction by sodium dithionite (in the case of **3**) or to exchange with free biotin (in the case of the **2:AF** complex).¹⁹ Upon




Figure 2. Fluorescence microscopy images of HeLa cells treated with **2:AF** and **3** at 0 μ M (a,d), 10 μ M (b,e), and 100 μ M (c,f), respectively. Cells were fixed with paraformaldehyde (4% w/v) and stained with DAPI (nucleus, blue channel; a–f). Overlay images clearly show that material is excluded from the nucleus. Images were taken at the same exposure for different concentrations of the lipid constructs. Bar, 10 μ m (see panel a, bottom right).

reduction with 5 mM sodium dithionite, a reagent known to extinguish NBD fluorescence, 59% of the fluorescence from the cells was lost. Biotin exchange for 1 h resulted in a similar (73%) loss of fluorescence in the case of the **2:AF** treated cells. Assuming NBD fluorescence is not affected by the environment and accounting for self-quenching in 100 μ M solutions of **3**, treatment with a 100 μ M solution resulted in $\geq 10^6$ molecules on the surface of each cell, available for reduction. The localization of synthetic constructs and macromolecular cargo inside cells was investigated using microscopy done in the presence of a nucleus specific dye, 4',6-diamidino-2-phenylindole (DAPI). As the overlay images show in Figure 2, light emitted by **3** and **2:AF** originates from the cytoplasmic region and the agents are excluded entirely from the nucleus.

In general, the fluorinated lipid constructs **2** and **3** were more efficient in transport and uptake as compared to their hydrocarbon counterparts **4** and **5**. As judged from fluorescence counting, this difference was 2.6-fold. This difference in efficiency of uptake was also confirmed using flow cytometry (Figure 3). While the hydrocarbon lipids conferred a 13-fold increase in mean fluorescence intensity of cells over background, the cells treated with the fluorinated congeners were intensely fluorescent with a 63-fold increase in mean fluorescence (a difference of 4.8-fold over the




Figure 3. Flow cytometry of HeLa cells (typically 3×10^4) suspended in phosphate buffered saline treated with **8** and **3** (panel a) and with **3** and **5** (panel b). Cells treated with the fluorinated construct **3** were 4.8-fold more intensely fluorescent than those treated with the hydrocarbon analogue **5**.

hydrocarbon version). These results demonstrate the superior ability of the fluorinated lipids to trigger and act as participants in the endocytic events.

In summary, we report a new class of macromolecular transport agents capable of entering living cells through endocytosis. They are furthermore able to facilitate the entry of noncovalently bound proteins. The delivery agents were nontoxic and were distributed both on the surface and in the cytoplasm of cells but not in the nucleus. Fluorinated lipids were found to be superior in facilitating transport in this manner. A large number of molecules can be displayed on the cell surface using this methodology ($\sim 10^6$). This study paves the way for the clustered display of ligands on cell surfaces and intracellular delivery of macromolecules for imaging and therapeutic applications. These constructs may be especially useful for delivering short interfering RNAs (siRNAs), as the main events in RNAi are localized in the cytoplasm. Studies along these lines are in progress in our laboratories.

Acknowledgment. We thank Profs. David Lee, David Walt, and Kyongbum Lee for the generous use of their facilities and Stephen Kwok, Dr. Alenka Lovy-Wheeler, and Dr. Ragnhild Whitaker for their help with flow cytometry and microscopy. We thank Eliza Vasile for maintaining the MIT/CCR Microscopy and Imaging core facility. A.K.L.L. is a special fellow of the Leukemia and Lymphoma Society. This work was supported in part by the NIH (CA125033 and GM65500). The ESI-MS and NMR facilities at Tufts are supported by the NSF (0320783 and 0821508). This paper is dedicated to Prof. Matthew Zimmt (Brown University) on the occasion of his 50th birthday.

Supporting Information Available: Experimental procedures, synthesis and analytical data for compounds, and movies of different

focal planes in the z-axes of Figure 2. This material is available free of charge via the Internet at <http://pubs.acs.org>.

References

- (1) Conner, S. D.; Schmid, S. L. *Nature* **2003**, *422*, 37–44.
- (2) Smith, D. A.; van de Waterbeemd, H. *Curr. Opin. Chem. Biol.* **1999**, *3*, 373–378.
- (3) Doerr, A. *Nat. Methods* **2006**, *3*, 770–771.
- (4) Kam, N. W. S.; Liu, Z. A.; Dai, H. J. *Angew. Chem., Int. Ed.* **2006**, *45*, 577–581.
- (5) Morris, M. C.; Depollier, J.; Mery, J.; Heitz, F.; Divita, G. *Nat. Biotechnol.* **2001**, *19*, 1173–1176.
- (6) Yan, X. H.; He, Q.; Wang, K. W.; Duan, L.; Cui, Y.; Li, J. B. *Angew. Chem., Int. Ed.* **2007**, *46*, 2431–2434.
- (7) Rothbard, J. B.; Garlington, S.; Lin, Q.; Kirschberg, T.; Kreider, E.; McGrane, P. L.; Wender, P. A.; Khavari, P. A. *Nat. Med.* **2000**, *6*, 1253–1257.
- (8) Okuyama, M.; Laman, H.; Kingsbury, S. R.; Visintin, C.; Leo, E.; Eward, K. L.; Stoerber, K.; Boshoff, C.; Williams, G. H.; Selwood, D. L. *Nat. Methods* **2007**, *4*, 153–159.
- (9) Feazell, R. P.; Nakayama-Ratchford, N.; Dai, H.; Lippard, S. J. *J. Am. Chem. Soc.* **2007**, *129*, 8438.
- (10) Kostarelos, K.; Lacerda, L.; Pastorin, G.; Wu, W.; Wieckowski, S.; Luangsivilay, J.; Godefroy, S.; Pantarotto, D.; Briand, J. P.; Muller, S.; Prato, M.; Bianco, A. *Nat. Nanotechnol.* **2007**, *2*, 108–113.
- (11) Chen, X.; Tam, U. C.; Czapinski, J. L.; Lee, G. S.; Rabuka, D.; Zettl, A.; Bertozzi, C. R. *J. Am. Chem. Soc.* **2006**, *128*, 6292–6293.
- (12) Kam, N. W. S.; O'Connell, M.; Wisdom, J. A.; Dai, H. J. *Proc. Natl. Acad. Sci. U.S.A.* **2005**, *102*, 11600–11605.
- (13) Liu, Z.; Cai, W. B.; He, L. N.; Nakayama, N.; Chen, K.; Sun, X. M.; Chen, X. Y.; Dai, H. J. *Nat. Nanotechnol.* **2007**, *2*, 47–52.
- (14) Jones, M. N. *Liposomes*, Pt E; Elsevier Academic Press Inc: San Diego, CA, 2005; Vol. 391, pp 211–228.
- (15) Torchilin, V. P. *Nat. Rev. Drug Discovery* **2005**, *4*, 145–160.
- (16) Ng, P. P.; Dela Cruz, J. S.; Sorour, D. N.; Stinebaugh, J. M.; Shin, S. U.; Shin, D. S.; Morrison, S. L.; Penichet, M. L. *Proc. Natl. Acad. Sci. U.S.A.* **2002**, *99*, 10706–10711.
- (17) Mayor, S.; Pagano, R. E. *Nat. Rev. Mol. Cell Biol.* **2007**, *8*, 603–612.
- (18) Peterson, B. R. *Org. Biomol. Chem.* **2005**, *3*, 3607–3612.
- (19) Boonyarattanakalin, S.; Martin, S. E.; Dykstra, S. A.; Peterson, B. R. *J. Am. Chem. Soc.* **2004**, *126*, 16379–16386.
- (20) Sun, Q.; Cai, S.; Peterson, B. R. *J. Am. Chem. Soc.* **2008**, *130*, 10064–10065.
- (21) Nabi, I. R.; Le, P. U. *J. Cell Biol.* **2003**, *161*, 673–677.
- (22) Pelkmans, L.; Fava, E.; Grabner, H.; Hannus, M.; Habermann, B.; Krausz, E.; Zerial, M. *Nature* **2005**, *436*, 78–86.
- (23) (a) Yoder, N. C.; Kalsani, V.; Schuy, S.; Vogel, R.; Janshoff, A.; Kumar, K. *J. Am. Chem. Soc.* **2007**, *129*, 9037–9043. (b) Yoder, N. C.; Yüksel, D.; Dafik, L.; Kumar, K. *Curr. Opin. Chem. Biol.* **2006**, *10*, 576–583. (c) Schuy, S.; Faiss, S.; Yoder, N. C.; Kalsani, V.; Kumar, K.; Janshoff, A.; Vogel, R. *J. Phys. Chem. B* **2008**, *112*, 8250–8256.
- (24) Schuy, S.; Faiss, S.; Yoder, N. C.; Kalsani, V.; Kumar, K.; Janshoff, A.; Vogel, R. *J. Phys. Chem. B* **2008**, *112*, 8250–8256.
- (25) Bilgiçer, B.; Fichera, A.; Kumar, K. *J. Am. Chem. Soc.* **2001**, *123*, 4393–4399.
- (26) Bilgiçer, B.; Kumar, K. *Tetrahedron* **2002**, *58*, 4105–4112.
- (27) Bilgiçer, B.; Kumar, K. *Proc. Natl. Acad. Sci. U.S.A.* **2004**, *101*, 15324–15329.
- (28) Bilgiçer, B.; Xing, X.; Kumar, K. *J. Am. Chem. Soc.* **2001**, *123*, 11815–11816.
- (29) Myers, K. E.; Kumar, K. *J. Am. Chem. Soc.* **2000**, *122*, 12025–12026.
- (30) Krafft, M. P. *Adv. Drug Delivery Rev.* **2001**, *47*, 209–228.
- (31) Grant, A. M.; Hanson, P. K.; Nichols, J. W. *Traffic* **2008**, *2*, 37–50.
- (32) Hanson, P. K.; Grant, A. M.; Nichols, J. W. *J. Cell Sci.* **2002**, *115*, 2725–2733.
- (33) Liu, X. Y.; Stocker, B. L.; Seeberger, P. H. *J. Am. Chem. Soc.* **2006**, *128*, 3638–3648.
- (34) Smythe, E.; Warren, G. *Eur. J. Biochem.* **1991**, *202*, 689–699.
- (35) Schmid, S. L.; Carter, L. L. *J. Cell Biol.* **1990**, *111*, 2307–2318.
- (36) Heuser, J. E.; Anderson, R. G. W. *J. Cell Biol.* **1989**, *108*, 389–400.
- (37) Hussey, S. L.; Peterson, B. R. *J. Am. Chem. Soc.* **2002**, *124*, 6265–6273.
- (38) Powers, D. D.; Willard, B. L.; Carbonell, R. G.; Kilpatrick, P. K. *Biotechnol. Prog.* **1992**, *8*, 436–453.

JA902777D